National strategies

There is no simple or standard solution that is applicable to all countries to eliminate the problem. Each country has to develop a strategy based on its own situation taking into account the available infrastructure and human and other resources. This should be part of the overall national drug quality assurance system.

In developing a national strategy, assessment of the current situation should be the starting point. All concerned parties: government agencies, pharmaceutical industries, drug suppliers, health care providers and professionals, consumers, nongovernmental and international organisations should be involved in the process of development and implementation of the plan. The plan should have clear and realistic goals that are attainable. The role of each party must be clearly defined to ensure accountability. Progress on implementations of the plan of action should be monitored and evaluated from time to time to identify successes or failures and take timely corrective actions.

Attachments:

Anti-Counterfeiting Strategy (1).pdf

[Evidence suggests that the availability of counterfeit medicines and medical devices is a growing threat worldwide, with the World Health Organisation (WHO) leading the International Medical Products Anti-counterfeiting Taskforce (IMPACT) to combat it.]

191 Kb